ELI LILLY & CO (LLY) Stock Price, Quote, News and Overview
NYSE:LLY - New York Stock Exchange, Inc. - US5324571083 - Common Stock - Currency: USD
LLY Quote, Performance and Key Statistics
713.71
-1.49 (-0.21%)
The current stock price of LLY is 713.71 USD. In the past month the price decreased by -19.31%. In the past year, price decreased by -11.61%.
LLY Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| JNJ | JOHNSON & JOHNSON | 15.22 | 367.98B | ||
| NVO | NOVO-NORDISK A/S-SPONS ADR | 19.24 | 299.26B | ||
| NVS | NOVARTIS AG-SPONSORED ADR | 13.57 | 222.69B | ||
| AZN | ASTRAZENECA PLC-SPONS ADR | 18.93 | 218.30B | ||
| MRK | MERCK & CO. INC. | 9.96 | 194.81B | ||
| PFE | PFIZER INC | 7.26 | 132.58B | ||
| SNY | SANOFI-ADR | 13.57 | 126.50B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 6.38 | 95.34B | ||
| GSK | GSK PLC-SPON ADR | 7.02 | 78.45B | ||
| ZTS | ZOETIS INC | 27.01 | 72.38B | ||
| HLN | HALEON PLC-ADR | 22.73 | 50.17B | ||
| TAK | TAKEDA PHARMACEUTIC-SP ADR | 26.49 | 45.51B |
Related stock screener links
About LLY
Company Profile
Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The company is headquartered in Indianapolis, Indiana and currently employs 47,000 full-time employees. Its cardiometabolic health products include Basaglar; Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, and others; Humulin, Humulin 70/30, and others; Jardiance; Mounjaro; Trulicity; and Zepbound. Its oncology products include Cyramza, Erbitux, Tyvyt, and Verzenio. Its immunology products include Ebglyss, Olumiant, Omvoh, and Taltz. Its neuroscience products include Emgality and Kisunla. The Company, through its subsidiary, POINT Biopharma Global Inc., is engaged in radiopharmaceutical discovery, development, and manufacturing efforts, as well as clinical and pre-clinical radioligand therapies in development for the treatment of cancer. The company is also developing an oral small molecule inhibitor of α4β7 integrin for inflammatory bowel disease (IBD). The company also owns a lead therapeutic molecule FXR314.
Company Info
ELI LILLY & CO
Lilly Corporate Ctr, Drop Code 1094
Indianapolis INDIANA 46285 US
CEO: David A. Ricks
Employees: 47000
Phone: 13172762000
ELI LILLY & CO / LLY FAQ
What is the stock price of ELI LILLY & CO today?
The current stock price of LLY is 713.71 USD. The price decreased by -0.21% in the last trading session.
What is the ticker symbol for ELI LILLY & CO stock?
The exchange symbol of ELI LILLY & CO is LLY and it is listed on the New York Stock Exchange, Inc. exchange.
On which exchange is LLY stock listed?
LLY stock is listed on the New York Stock Exchange, Inc. exchange.
What is the price forecast or stock price prediction for ELI LILLY & CO stock?
33 analysts have analysed LLY and the average price target is 1013.54 USD. This implies a price increase of 42.01% is expected in the next year compared to the current price of 713.71. Check the ELI LILLY & CO stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is ELI LILLY & CO worth?
ELI LILLY & CO (LLY) has a market capitalization of 676.41B USD. This makes LLY a Mega Cap stock.
How many employees does ELI LILLY & CO have?
ELI LILLY & CO (LLY) currently has 47000 employees.
What are the support and resistance levels for ELI LILLY & CO (LLY) stock?
ELI LILLY & CO (LLY) has a support level at 713.7 and a resistance level at 720.91. Check the full technical report for a detailed analysis of LLY support and resistance levels.
Is ELI LILLY & CO (LLY) expected to grow?
The Revenue of ELI LILLY & CO (LLY) is expected to grow by 31.67% in the next year. Check the estimates tab for more information on the LLY EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy ELI LILLY & CO (LLY) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of LLY, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of LLY, evaluating the profitability, health, valuation and growth aspects
- ELI LILLY & CO (LLY) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- ELI LILLY & CO (LLY) Sales and EPS estimates to see what analysts future expectations are.
- ELI LILLY & CO (LLY) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- ELI LILLY & CO (LLY) Insider and Institutional Ownership to learn about the owners and their transactions.
- ELI LILLY & CO (LLY) Stock Chart to make your own analysis
- ELI LILLY & CO (LLY) Latest news and press-releases to stay up to date.
Does ELI LILLY & CO (LLY) stock pay dividends?
ELI LILLY & CO (LLY) has a dividend yield of 0.83%. The yearly dividend amount is currently 4.93. Check the full fundamental report for a detailed analysis of LLY dividend history, reliability and sustainability.
When does ELI LILLY & CO (LLY) report earnings?
ELI LILLY & CO (LLY) will report earnings on 2025-08-07, before the market open.
What is the Price/Earnings (PE) ratio of ELI LILLY & CO (LLY)?
The PE ratio for ELI LILLY & CO (LLY) is 51.87. This is based on the reported non-GAAP earnings per share of 13.76 and the current share price of 713.71 USD. Check the full fundamental report for a full analysis of the valuation metrics for LLY.
What is the Short Interest ratio of ELI LILLY & CO (LLY) stock?
The outstanding short interest for ELI LILLY & CO (LLY) is 0.78% of its float. Check the ownership tab for more information on the LLY short interest.
LLY Technical Analysis
LLY Fundamental Analysis
ChartMill assigns a fundamental rating of 6 / 10 to LLY. LLY has an excellent profitability rating, but there are some minor concerns on its financial health.
LLY Financial Highlights
Over the last trailing twelve months LLY reported a non-GAAP Earnings per Share(EPS) of 13.76. The EPS increased by 89.01% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 22.66% | ||
| ROA | 12.42% | ||
| ROE | 70.45% | ||
| Debt/Equity | 2.19 |
LLY Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 81% to LLY. The Buy consensus is the average rating of analysts ratings from 33 analysts.
For the next year, analysts expect an EPS growth of 68% and a revenue growth 31.67% for LLY